DURHAM, N.C., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Taylor Schreiber, MD, PhD, Vice President of Research and Development, and Eckhard Podack, MD, PhD, Scientific Founder, will be speaking at the 7th Annual Phacilitate Immunotherapy Forum 2015, being held at the Grand Hyatt Hotel in Washington, D.C. from January 26-28, 2015.
|Date and Time:||Monday, January 26 @ 2:30pm Eastern Time|
|Session:||Session 2, Clinical Updates in Specific Therapeutic Areas – Mechanistic Approaches and Innovative Trial Design: Lung Cancer|
|Presentation Title:||Phase II Progress in Late Stage NSCLC with Combination Viagenpumatucel-L and Low-Dose Metronomic Cyclophosphamide|
|Presenter:||Taylor H. Schreiber, MD, PhD|
|Vice President of Research and Development|
|Heat Biologics, Inc.|
|Date and Time:||Tuesday, January 27 @ 12:10pm Eastern Time|
|Session:||De-Risking Combination Strategies – Adopting a More Mechanistic & Rational Approach to Targeted + Systemic Immunotherapy Combinations|
|Presentation Title:||Gp96-Ig Vaccines in Combination with Extracellular Adenosine Blockade Cause Complete Tumor Rejection|
|Presenter:||Eckhard R. Podack, MD, PhD|
|Heat Biologics, Inc.|
|Sylvester Distinguished Professor of Medicine|
|Chairman, Department of Microbiology & Immunology|
|University of Miami|
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed and the other factors described in our annual report on Form 10-K for the year ended December 31, 2013 and our other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: Heat Biologics, Inc. Contact Information: Matthew Czajkowski Chief Financial Officer (919) 240-7133 email@example.com Investor Relations Michael Wood LifeSci Advisors LLC (646) 597-6983